NatWest Group’s Immunogen Inc IMGN Stock Holding History

NatWest Group’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-91,856	Closed	-$973	–	505
2014 Q3	$973	Buy	91,856 +17,640	+24%	+$200K	0.01%	263
2014 Q2	$879K	Buy	74,216 +5,298	+8%	+$66.5K	0.04%	279
2014 Q1	$1.03M	Buy	68,918 +9,626	+16%	+$152K	0.05%	245
2013 Q4	$870K	Buy	59,292 +5,529	+10%	+$85K	0.02%	470
2013 Q3	$915K	Sell	53,763 -7,722	-13%	-$136K	0.03%	462
2013 Q2	$1.02M	Buy	+61,485	New	+$996K	0.01%	462

Other funds holding IMGN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

NatWest Group's IMGN Position: Q4 2014 in Review

NatWest Group sold out of Immunogen Inc (IMGN) in Q4 2014, closing a stake of 91,856 shares — an estimated $973 sold.

NatWest Group first reported a position in IMGN in Q2 2013 and held it in 6 quarters. The position peaked at $1.03M in Q1 2014. 131 funds tracked by Wall St. Rank hold IMGN as of Q4 2014.

NatWest Group reported no remaining Immunogen Inc position as of Q4 2014 after selling out during the quarter.
NatWest Group sold 91,856 Immunogen Inc shares in Q4 2014, an estimated $973.
NatWest Group first reported a position in Immunogen Inc in Q2 2013 and held it in 6 quarters.
NatWest Group's Immunogen Inc position peaked at $1.03M in Q1 2014.
131 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2014.

Based on NatWest Group's 13F filing for Q4 2014, filed 12 Feb 2015.